Indefinite Delivery Contract SPE2DR25D9637

Award Date 8/1/25
Last Date to Order 12/31/36
Ultimate Awardee
Not listed
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
The Indefinite Delivery Contract (IDC) SPE2DR25D9143 was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The IDC, valued at $4,999,999, has an ultimate completion date of December 31, 2036 and covers the delivery of a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to support the medical...
This Indefinite Delivery Contract (IDC) was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $499,999,999, covers the delivery of a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables to support the medical supply needs of military health facilities worldwide. The contract...
This Indefinite Delivery Contract (IDC) was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business located in Park Ridge, Illinois. The $4,999,999 contract, valid through December 31, 2036, covers the delivery of a comprehensive range of pharmaceutical products to support the medical supply needs of military health facilities worldwide. This includes branded and generic prescription drugs, over-the-counter medications, biologics, and...
This Indefinite Delivery Contract (IDC) awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business, provides a comprehensive range of pharmaceutical products and medical supplies to support the recurring medical needs of military healthcare facilities and veterans' medical centers nationwide. The $499,999,999 single-award IDC, valid through November 2026, enables DLA to issue firm fixed-price delivery orders for branded and generic prescription...
This Indefinite Delivery Contract (IDC) was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $499,999,999, covers a wide range of pharmaceutical products and medical supplies to support the recurring medical needs of military healthcare facilities and veterans' medical centers nationwide. The contract enables the DLA to issue firm fixed-price delivery orders for branded and generic...
This Indefinite Delivery Contract (IDC) was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business located in Park Ridge, Illinois. The $499,999,999 contract, valid through November 2026, enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items to support the medical supply needs of military health facilities worldwide. The contract covers an extensive portfolio of branded and generic...
This Indefinite Delivery Contract (IDC) was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, to provide a comprehensive range of pharmaceutical products and medical supplies to support the medical needs of Department of Defense (DoD) healthcare facilities worldwide. The IDC, valued at $499,999,999 and valid through November 2026, enables DLA to issue firm fixed-price delivery orders for branded and generic...
The Indefinite Delivery Contract (IDC) SPE2DU25D9809 was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $4,999,999, provides a broad range of pharmaceutical products and medical supplies to support the recurring medical needs of military healthcare facilities and veterans' medical centers nationwide. The IDC is part of the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G...
This Indefinite Delivery Contract (IDC) was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Illinois. The contract, valued at $499,999,999, covers a comprehensive range of pharmaceutical products and medical supplies to support the recurring medical needs of military healthcare facilities and veterans' medical centers nationwide. The IDC enables DLA to issue firm fixed-price delivery orders for...
The provided Indefinite Delivery Contract (IDC) was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The single-award IDC, valued at $499,999,999, covers a comprehensive range of pharmaceutical products including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables to support the recurring medical supply needs of military healthcare facilities and veterans'...

The Indefinite Delivery Contract (IDC) SPE2DR25D9637 was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $4,999,999.00, is for the delivery of a comprehensive range of pharmaceutical products and medical supplies to support the recurring medical needs of military healthcare facilities and veterans' medical centers worldwide.

This IDC is part of the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) procurement, which aims to establish multiple Prime Vendor Contracts to provide worldwide pharmaceutical support to various Department of Defense (DoD) customers, including the Defense Health Agency, U.S. Coast Guard, and U.S. Naval Fleet. The contracted products include branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables across various categories such as injections, tablets, creams, auto-injectors, and specialty medications. The contract has a base period of 30 months and three 30-month option periods, with an estimated total value of $30.3 billion for all awarded contracts.

Generated 6/6/25, 9:42 AM